| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 62.000 +17.24% on 04/02/26 | | 82.000 -11.36% on 04/22/26 | +8.686 (+13.57%) since 04/01/26 |
| 3-Month | 48.000 +51.43% on 02/02/26 | | 82.000 -11.36% on 04/22/26 | +20.786 (+40.05%) since 01/30/26 |
| 52-Week | 26.000 +179.56% on 05/27/25 | | 84.000 -13.47% on 12/17/25 | +39.686 (+120.26%) since 05/01/25 |
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer...
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms,...
| 3rd Resistance Point | 77.307 |
| 2nd Resistance Point | 75.653 |
| 1st Resistance Point | 74.827 |
| Last Price | 72.686 |
| 1st Support Level | 72.347 |
| 2nd Support Level | 70.693 |
| 3rd Support Level | 69.867 |
| 52-Week High | 84.000 |
| Last Price | 72.686 |
| Fibonacci 61.8% | 61.844 |
| Fibonacci 50% | 55.000 |
| Fibonacci 38.2% | 48.156 |
| 52-Week Low | 26.000 |